A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
J. R. Brown(Harvard University), AS Freedman(Harvard University), Stacey M. Fernandes(Dana-Farber Cancer Institute), Laura Z. Rassenti(University of California San Diego), Lillian Werner(Dana-Farber Cancer Institute), Thomas J. Kipps(University of California San Diego), Bradley T. Messmer(Harvard University), Philippe Armand(Harvard University), Donna Neuberg(Otsuka (Japan)), Bethany Tesar(Harvard University), Evgeny Mikler(Harvard University), Vanessa K. Dalton(University of Michigan), Ann S. LaCasce(Otsuka (Japan)), Jeffrey G. Supko(Harvard University), David C. Fisher(Dana-Farber Cancer Institute), E. Jacobsen(Harvard University), Sean M. McDonough(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Jerome Ritz(Dana-Farber Cancer Institute)
Cited by 14
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k